Ardelyx Stock Forecast, Price & News

Ardelyx (NASDAQ:ARDX) Frequently Asked Questions

Is Ardelyx a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ardelyx stock.
View analyst ratings for Ardelyx or view top-rated stocks.

How has Ardelyx's stock price been impacted by COVID-19 (Coronavirus)?

Ardelyx's stock was trading at $5.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ARDX shares have decreased by 74.6% and is now trading at $1.52.
View which stocks have been most impacted by COVID-19.

Are investors shorting Ardelyx?

Ardelyx saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 5,890,000 shares, a drop of 23.4% from the October 31st total of 7,690,000 shares. Based on an average trading volume of 3,370,000 shares, the days-to-cover ratio is currently 1.7 days. Approximately 6.5% of the company's shares are short sold.
View Ardelyx's Short Interest.

When is Ardelyx's next earnings date?

Ardelyx is scheduled to release its next quarterly earnings announcement on Monday, March 14th 2022.
View our earnings forecast for Ardelyx.

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) posted its earnings results on Friday, November, 12th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by $0.07. Ardelyx had a negative trailing twelve-month return on equity of 132.31% and a negative net margin of 1,386.48%.
View Ardelyx's earnings history.

What price target have analysts set for ARDX?

8 Wall Street analysts have issued 1-year price targets for Ardelyx's shares. Their forecasts range from $2.00 to $14.00. On average, they anticipate Ardelyx's share price to reach $7.09 in the next year. This suggests a possible upside of 366.3% from the stock's current price.
View analysts' price targets for Ardelyx or view top-rated stocks among Wall Street analysts.

Who are Ardelyx's key executives?

Ardelyx's management team includes the following people:

• Mike Raab, President, Chief Executive Officer & Director
• Justin A. Renz, Chief Financial & Accounting Officer
• Jeffrey W. Jacobs, Chief Scientific Officer (LinkedIn Profile)
• Elizabeth Grammer, Secretary, Chief Legal & Administrative Officer (LinkedIn Profile)
• David P. Rosenbaum, Chief Development Officer (LinkedIn Profile)

Who are some of Ardelyx's key competitors?

Some companies that are related to Ardelyx include Imago BioSciences (IMGO), Chinook Therapeutics (KDNY), Dyne Therapeutics (DYN), Kezar Life Sciences (KZR), Emisphere Technologies (EMIS), Atea Pharmaceuticals (AVIR), Kronos Bio (KRON), Janux Therapeutics (JANX), Zogenix (ZGNX), Cara Therapeutics (CARA), Prelude Therapeutics (PRLD), Lexicon Pharmaceuticals (LXRX), VBI Vaccines (VBIV), Eagle Pharmaceuticals (EGRX) and Collegium Pharmaceutical (COLL).
View all of ARDX's competitors.

What other stocks do shareholders of Ardelyx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD).

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.26%), Morgan Stanley (2.21%), Geode Capital Management LLC (1.71%), Pekin Hardy Strauss Inc. (1.23%), Congress Asset Management Co. MA (0.93%) and Millennium Management LLC (0.88%). Company insiders that own Ardelyx stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Jeffrey W Jacobs, Justin A Renz, Michael Raab, Robert Blanks, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends for Ardelyx.

Which institutional investors are selling Ardelyx stock?

ARDX stock was sold by a variety of institutional investors in the last quarter, including 683 Capital Management LLC, Dimensional Fund Advisors LP, Citigroup Inc., Voya Investment Management LLC, Millennium Management LLC, Personal CFO Solutions LLC, California State Teachers Retirement System, and Alliancebernstein L.P.. Company insiders that have sold Ardelyx company stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, and Michael Raab.
View insider buying and selling activity for Ardelyx or view top insider-selling stocks.

Which institutional investors are buying Ardelyx stock?

ARDX stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Two Sigma Investments LP, Congress Asset Management Co. MA, Point72 Asset Management L.P., Geode Capital Management LLC, BlackRock Inc., Pekin Hardy Strauss Inc., and Goldman Sachs Group Inc..
View insider buying and selling activity for Ardelyx or or view top insider-buying stocks.

How do I buy shares of Ardelyx?

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $1.52.

How much money does Ardelyx make?

Ardelyx has a market capitalization of $171.37 million and generates $7.57 million in revenue each year. The biopharmaceutical company earns $-94.31 million in net income (profit) each year or ($1.53) on an earnings per share basis.

How many employees does Ardelyx have?

Ardelyx employs 129 workers across the globe.

What is Ardelyx's official website?

The official website for Ardelyx is www.ardelyx.com.

Where are Ardelyx's headquarters?

Ardelyx is headquartered at 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at (510) 745-1700, via email at [email protected], or via fax at 510-745-0493.